The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability by Singh, T et al.
  
The contribution of rare variants to risk of 1 
schizophrenia in individuals with and without 2 
intellectual disability 3 
Tarjinder Singh1, James T. R. Walters2, Mandy Johnstone3, David Curtis4,5, Jaana 4 
Suvisaari6, Minna Torniainen6, Elliott Rees2, Conrad Iyegbe7, Douglas 5 
Blackwood3, Andrew M. McIntosh8, Georg Kirov2, Daniel Geschwind9, Robin M. 6 
Murray7, Marta Di Forti7, Elvira Bramon10, Michael Gandal9, Christina M. 7 
Hultman11, Pamela Sklar12, INTERVAL Study13, UK10K Consortium13, Aarno 8 
Palotie14,15, Patrick F. Sullivan16,17, Michael C. O'Donovan2, Michael J. Owen2, 9 
Jeffrey C. Barrett1 10 
1Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton 11 
CB10 1HH, Cambridge, UK. 2MRC Centre for Neuropsychiatric Genetics and 12 
Genomics, Division of Psychological Medicine and Clinical Neurosciences, School 13 
of Medicine, Cardiff University, Cardiff CF24 4HQ, UK. 3Division of Psychiatry, 14 
The University of Edinburgh, Royal Edinburgh Hospital, Edinburgh EH10 5HF, 15 
UK. 4University College London (UCL) Genetics Institute, University College 16 
London, Darwin Building, Gower Street, London WC1E 6BT, UK. 5Centre for 17 
Psychiatry, Barts and the London School of Medicine and Dentistry, London, UK. 18 
6National Institute for Health and Welfare (THL), Helsinki FI-00271, Finland. 19 
7Institute of Psychiatry, King's College London, 16 De Crespigny Park, London 20 
SE5 8AF, UK. 8Centre for Cognitive Ageing and Cognitive Epidemiology, The 21 
University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ , UK. 9UCLA David 22 
Geffen School of Medicine, Los Angeles, California 90095, USA. 10Division of 23 
Psychiatry, University College London, Charles Bell House, Riding House Street, 24 
London W1W 7EJ, UK. 11Department of Medical Epidemiology and Biostatistics, 25 
Karolinska Institutet, SE-17177 Stockholm, Sweden. 12Division of Psychiatric 26 
Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 27 
New York, New York 10029, USA. 13The members of this consortium are listed in 28 
the Supplementary Note. 14Institute for Molecular Medicine Finland (FIMM), 29 
University of Helsinki, Helsinki FI-00014 Finland. 15Program in Medical and 30 
Population Genetics and Genetic Analysis Platform, The Broad Institute of MIT 31 
and Harvard, Cambridge MA 02132, USA. 16Department of Medical Epidemiology 32 
and Biostatistics, Karolinska Institutet, SE-17177 Stockholm, Sweden. 33 
17Departments of Genetics and Psychiatry, University of North Carolina, Chapel 34 
Hill, NC, 27599-7264, USA.  35 
Correspondence should be addressed to Tarjinder Singh (ts14@sanger.ac.uk) 36 
and Jeffrey C. Barrett (barrett@sanger.ac.uk). 37 
Abstract 38 
 39 
By meta-analyzing rare coding variants in whole-exome sequences of 40 
4,133 schizophrenia cases and 9,274 controls, de novo mutations in 1,077 trios, 41 
and copy number variants from 6,882 cases and 11,255 controls, we show that 42 
individuals with schizophrenia carry a significant burden of rare damaging 43 
variants in 3,488 genes previously identified as having a near-complete 44 
  
depletion of loss-of-function variants. In schizophrenia patients who also have 45 
intellectual disability, this burden is concentrated in risk genes associated with 46 
neurodevelopmental disorders. After excluding known neurodevelopmental 47 
disorder risk genes, a significant rare variant burden persists in other loss-of-48 
function intolerant genes, and while this effect is notably stronger in 49 
schizophrenia patients with intellectual disability, it is also seen in patients who 50 
do not have intellectual disability. Together, our results show that rare damaging 51 
variants contribute to the risk of schizophrenia both with and without 52 
intellectual disability, and support an overlap of genetic risk between 53 
schizophrenia and other neurodevelopmental disorders.  54 
 55 
Introduction 56 
 57 
Schizophrenia is a common and debilitating psychiatric illness 58 
characterized by positive symptoms (hallucinations, delusions, disorganized 59 
speech and behaviour), negative symptoms (social withdrawal and diminished 60 
emotional expression), and cognitive impairment that result in social and 61 
occupational dysfunction1,2. Operational diagnostic criteria for the disorder as 62 
described in the DSM-V require the presence of at least two of the core 63 
symptoms over a period of six months with at least one month of active 64 
symptoms3. It is increasingly recognized that current categorical psychiatric 65 
classifications have a number of shortcomings, in particular that they overlook 66 
the increasing evidence for etiological and mechanistic overlap between 67 
psychiatric disorders4.  68 
 69 
A diverse range of pathophysiological processes may contribute to the 70 
clinical features of schizophrenia5. Indeed, previous studies have suggested a 71 
number of hypotheses about schizophrenia pathogenesis, including abnormal 72 
pre-synaptic dopaminergic activity6, postsynaptic mechanisms involved in 73 
synaptic plasticity7, dysregulation of synaptic pruning8, and disruption to early 74 
brain development9,10. This complexity is underpinned by the varied nature of 75 
genetic contributions to risk of schizophrenia. Genome-wide association studies 76 
have identified over 100 independent loci defined by common (minor allele 77 
frequency [MAF] > 1%) single nucleotide variants (SNVs)11, and a recent analysis 78 
determined that more than 71% of all one-megabase regions in the genome 79 
contain at least one common risk allele12. The modest effects of these variants 80 
(median odds ratio [OR] = 1.08) combine to produce a polygenic contribution 81 
that explains only a fraction (ℎ௚ଶ = 0.274) of the overall liability12. In addition, a 82 
number of rare variants have been identified that have far larger effects on 83 
individual risk. These are best exemplified by eleven large, rare recurrent copy 84 
number variants (CNVs) but evidence from whole-exome sequencing studies 85 
implies that many other rare coding SNVs and de novo mutations also confer 86 
substantial individual risk13–17. There is growing evidence that some of the same 87 
genes and pathways are affected by both common and rare variants7,18. Pathway 88 
analyses of common variants and hypothesis-driven gene set analyses of rare 89 
variants have begun to enumerate some of these specific biological processes, 90 
including histone methylation, transmission at glutamatergic synapses, calcium 91 
channel signaling, synaptic plasticity, and translational regulation by the fragile X 92 
mental retardation protein (FMRP)11,13,14,19,20. 93 
  
 94 
In addition to exploring the biological mechanisms underlying 95 
schizophrenia, genetic analyses can also be used to understand its relationship to 96 
other neuropsychiatric and neurodevelopmental disorders. For instance, 97 
schizophrenia, bipolar disorder, and autism (ASD) show substantial sharing of 98 
common risk variants21,22. Sequencing studies of neurodevelopmental disorders 99 
suggest that this sharing of genetic risk may extend to rare variants of large 100 
effect. In the largest sequencing study of ASD to date, 20 of the 46 genes and all 101 
six CNVs implicated (false discovery rate [FDR] < 5%) had been previously 102 
described as dominant causes of developmental disorders23. Furthermore, an 103 
analysis of 60,706 whole exomes led by the ExAC consortium identified 3,230 104 
genes with near-complete depletion of protein-truncating variants, and de novo 105 
loss-of-function (LoF) mutations identified in individuals with ASD or 106 
developmental disorders were concentrated in this set of “LoF intolerant” 107 
genes23–25. Similarly, evidence from rare variants for a broader shared genetic 108 
etiology between schizophrenia and neurodevelopmental disorders has begun to 109 
emerge. Analyses of whole-exome data provided support for an enrichment of 110 
schizophrenia rare variants in intellectual disability genes, and schizophrenia 111 
cases were also found to have a higher concentration of ultra-rare disruptive 112 
SNVs in the ExAC LoF intolerant genes compared to controls13,17,26.  113 
 114 
However, the contribution of these rare variants to risk in the wider 115 
population of individuals diagnosed with schizophrenia, including those without 116 
intellectual disability, remains unclear. Intriguingly, the 11 rare CNVs found to be 117 
highly penetrant for schizophrenia also increased risk for intellectual disability 118 
and other congenital defects16,27, and more recently, a meta-analysis of whole-119 
exome sequence data showed that LoF variants in SETD1A conferred substantial 120 
risk for both schizophrenia and neurodevelopmental disorders18. Concurrent 121 
analyses of autism whole-exome data found that de novo loss-of-function (LoF) 122 
mutations identified in ASD probands, particularly those that disrupt genes 123 
associated with neurodevelopmental disorders, were disproportionately found 124 
in individuals with intellectual disability23,28. These emerging results raise the 125 
possibility that rare schizophrenia risk variants may be concentrated in a subset 126 
of schizophrenia patients with co-morbid intellectual disability. Here, we present 127 
the one of the largest accumulation of schizophrenia rare variant data to date, 128 
which we jointly analyze with phenotype data on cognitive function. Using this 129 
data set, we attempt to identify groups of genes disrupted by schizophrenia rare 130 
risk variants, and determine if a subset of patients disproportionately carry 131 
these damaging alleles.  132 
 133 
Results 134 
 135 
Study design 136 
 137 
To maximize our power to detect enrichment of damaging variants in 138 
schizophrenia cases in groups of genes, we performed a meta-analysis of three 139 
different types of rare coding variant studies: (1) high-quality SNV calls from 140 
whole-exome sequences of 4,133 schizophrenia cases and 9,274 matched 141 
controls, (2) de novo mutations identified in 1,077 schizophrenia parent-proband 142 
  
trios (Figure 1), and (3) CNV calls from genotyping array data of 6,882 cases and 143 
11,255 controls.  The ascertainment of these samples, data production, and 144 
quality control were described previously18,29. All de novo mutations included in 145 
our analysis had been validated through Sanger sequencing, and stringent 146 
quality control steps were performed on the case-control data to ensure that 147 
sample ancestry and batch were closely matched between cases and controls 148 
(Online Methods).  149 
 150 
For each data type, we used appropriate methods to test for an excess of 151 
rare variants (Figure 1, Online Methods). In analyses of case-control SNV data, 152 
we applied an extension of the variant threshold burden test that corrected for 153 
exome-wide differences between cases and controls30. We tested all allele 154 
frequency thresholds below 0.1% observed in our data, and assessed statistical 155 
significance by permutation testing. In analyses of de novo SNV data, we 156 
compared the observed number of de novo mutations to random samples from 157 
an expected distribution based on a gene-specific mutation rate model to 158 
calculate an empirical P-value. For both types of whole-exome sequencing data, 159 
we restricted our analyses to loss-of-function variants. Finally, in analyses of 160 
case-control CNV data, we used a logistic regression framework that compares 161 
the rate of CNVs overlapping a specific gene set while correcting for differences 162 
in CNV size and number of genes disrupted7,19,31. To ensure our model was well 163 
calibrated, we restricted our analyses to small deletions and duplications 164 
overlapping fewer than seven genes with MAF < 0.1% (Supplementary Figure 1, 165 
Online Methods).  166 
 167 
We tested for an excess of rare damaging variants in schizophrenia 168 
patients in 1,766 gene sets (Online Methods, Supplementary Table 1, and 169 
detailed results below). Gene set P-values were computed using the three 170 
methods and variant definitions described above, and then meta-analyzed using 171 
Fisher’s Method to provide a single P-value for each gene set. Because we gave 172 
each data type equal weight, gene sets achieving significance typically show at 173 
least some signal in all three types of data. We observed a marked inflation in the 174 
quantile-quantile (Q-Q) plot of gene set P-values (Supplementary Figure 2), so 175 
we conducted two analyses to ensure our results were robust and not biased due 176 
to methodological or technical artifacts. First, we observed no inflation of P-177 
values when testing for enrichment of synonymous variants in our case-control 178 
and de novo analyses (Supplementary Figure 2). Second, we created random 179 
gene sets by sampling uniformly across the genome, and observed null 180 
distributions in Q-Q plots regardless of variant class and analytical method 181 
(Supplementary Figure 3). These findings suggested that our methods 182 
sufficiently corrected for known genome-wide differences in LoF and CNV 183 
burden between cases and controls, and other technical confounders like batch 184 
and ancestry.  185 
 186 
Rare, damaging schizophrenia variants are concentrated in LoF intolerant genes 187 
 188 
We first tested whether rare schizophrenia risk variants were 189 
consistently concentrated in genes defined loss-of-function intolerant across 190 
study design and variant type. Because some of our schizophrenia exome data 191 
  
was included in the ExAC database, we focused on the subset of 45,376 ExAC 192 
exomes without a known psychiatric diagnosis and that were not present in our 193 
study. From this subset, 3,488 genes were found to have near-complete 194 
depletion of such variants, which we defined as the LoF intolerant gene set. We 195 
found that rare damaging variants in schizophrenia cases were enriched in LoF 196 
intolerant genes (P < 3.6 × 10ିଵ଴, Table 1, Figure 2), with support in case-control 197 
SNVs (P < 5 × 10ି଻; OR 1.24, 1.16-1.31, 95% CI), case-control CNVs (P = 198 
2.6 × 10ିସ; OR 1.21, 1.15 – 1.28, 95% CI), and de novo mutations (P = 6.7 × 10ିଷ; 199 
OR 1.36, 1.1 – 1.68, 95% CI).  While this result was consistent with observations 200 
in intellectual disability and ASD24,32 the absolute effect size is smaller (e.g. de 201 
novos, Supplementary Figure 4 and 5). We observed no excess burden of rare 202 
damaging variants in the remaining 14,753 genes (Figure 2, Supplementary 203 
Figure 5). Furthermore, this signal was spread among many different LoF 204 
intolerant genes: if we rank genes by decreasing significance, the enrichment 205 
disappears in the case-control SNV analysis (P > 0.05) only after the exclusion of 206 
the top 50 genes. This suggests that the contribution of damaging rare variants in 207 
schizophrenia is not concentrated in just a handful of genes, but instead spread 208 
across many genes. 209 
 210 
Schizophrenia risk genes are shared with other neurodevelopmental disorders 211 
 212 
Given the significant enrichment of rare damaging variants in LoF 213 
intolerant genes in developmental disorders, autism and schizophrenia, we next 214 
asked whether these variants affected the same genes.  We found that autism 215 
risk genes identified from exome sequencing meta-analyses23 and genes in which 216 
LoF variants are known causes of severe developmental disorders as defined by 217 
the DDD study33,34 were significantly enriched for rare variants in individuals 218 
with schizophrenia (PASD = 9.5× 10ି଺; PDD = 2.3× 10ି଺; Table 1, Online Methods). 219 
Previous analyses have shown an enrichment of rare damaging variants in genes 220 
whose mRNA are bound by FMRP in both schizophrenia and autism35,13,32, so we 221 
sought to identify further shared biology by testing targets of neural regulatory 222 
genes previously implicated in autism32,36.  We observed enrichment of both 223 
such sets: promoter targets of CHD8 (P = 1.1× 10ି଺) and splice targets of RBFOX 224 
(P = 1.3× 10ିହ) (Table 1). We noted that some published gene lists attributed to 225 
same biological process differed due to choices of assay, cell type, method of 226 
sample extraction, and threshold of statistical significance, leading to distinct 227 
results in our gene set analyses. For example, we observed a significant 228 
enrichment in the published FMRP binding gene set based on mouse brain 229 
data37, but with no signal in one based on a human kidney cell line38. 230 
 231 
We also tested an additional 1,759 gene sets from databases of biological 232 
pathways with at least 100 genes, as we lacked power to detect weak 233 
enrichments in smaller sets (Online Methods). We observed enrichment of 234 
damaging rare variants in schizophrenia cases at FDR q < 0.05 in 35 of these 235 
gene sets (Supplementary Table 1, 2). These included previously implicated gene 236 
sets, like the NMDA receptor and ARC complexes13,14,35,37, as well as novel gene 237 
sets, such as genes involved in cytoskeleton (GO: 0007010), chromatin 238 
modification (GO:0016568), and chromatin organization (GO: 0006325). 239 
Furthermore, the gene sets most significantly enriched (FDR q < 0.01) for 240 
  
schizophrenia rare variants (Table 1) had all been previously linked to autism, 241 
intellectual disability, and severe developmental disorders23,32,33. Our 242 
enrichment results matched some of the findings from a pathway analysis of 243 
common risk variants in psychiatric disorders, which also implicated neuronal 244 
and chromatin gene sets20. However, unlike that study, we found no enrichment 245 
of rare variants in immune-related gene sets. 246 
 247 
We noticed that the 1,759 gene sets we tested were collectively enriched 248 
with LoF intolerant genes when compared to a random sampling of genes from 249 
the genome (Supplementary Figure 6 and 7). For some of the gene sets 250 
associated with schizophrenia, this over-representation was quite substantial:  251 
67% of the gene targets of FMRP and 74% of the genes associated with severe 252 
neurodevelopmental disorders are LoF intolerant. To better understand the 253 
consequences of this overlap on our results, we extended the gene set 254 
enrichment methods (Online Methods) to condition on LoF intolerance and 255 
brain-expression for the 35 gene sets with FDR q < 0.05 in the previous analysis 256 
(Supplementary Table 2). We first observed that 22 of the 35 gene sets remained 257 
significant even after conditioning on brain expression (Supplementary Tables 3, 258 
Online Methods), suggesting they represent more specific biological processes 259 
involved in schizophrenia. However, only known autism risk genes (P = 260 
4.4× 10ିସ) and neurodevelopmental disorder genes (P = 3× 10ିହ) had an excess 261 
of rare coding variants above the enrichment already observed in LoF intolerant 262 
genes (Supplementary Table 3). Thus, in addition to biological pathways 263 
implicated specifically in schizophrenia, at least a portion of the schizophrenia 264 
risk conferred by rare variants of large effect is shared with childhood onset 265 
disorders of neurodevelopment. 266 
 267 
Schizophrenia patients with intellectual disability have a greater burden of rare 268 
damaging variants 269 
 270 
In autism spectrum disorders, the observed excess of rare damaging 271 
variants has been shown to be greater in individuals with intellectual disability 272 
than those with normal levels of cognitive function28. We observed a similar 273 
phenomenon in schizophrenia cases carrying SETD1A LoF variants18, so next 274 
sought to explore whether this pattern is consistent in gene sets implicated in 275 
schizophrenia. We acquired relevant cognitive phenotype data for 2,971 of the 276 
4,131 schizophrenia patients with whole-exome sequencing data 277 
(Supplementary Figure 8). Of these individuals, 279 were clinically diagnosed 278 
with intellectual disability in addition to fulfilling the full diagnostic criteria for 279 
schizophrenia (SCZ-ID subgroup, Online Methods). We also identified 1,165 280 
individuals for whom we could rule out cognitive impairment (by excluding pre-281 
morbid IQ < 85, fewer than 12 years of schooling or lowest decile of composite 282 
cognitive measures, depending on available data, Online Methods). Finally, we 283 
identified 1,527 individuals who were not diagnosed with intellectual disability, 284 
but in whom some cognitive impairment could not be excluded.  285 
 286 
When stratifying into these three groups (intellectual disability, no 287 
intellectual disability but cognitive impairment not excluded, no cognitive 288 
impairment), we observed that the burden of rare damaging variants in LoF 289 
  
intolerant genes was significantly greater in the SCZ-ID subgroup than in the 290 
remaining schizophrenia cases (P = 2.6 × 10ିସ; OR 1.3, 1.12– 1.51, 95% CI) or 291 
controls (P < 5 × 10ି଻; OR 1.61, 1.37 – 1.89, 95% CI; Figure 3). In the LoF 292 
intolerant gene set, 0.27 (0.2 – 0.35, 95% CI) extra singleton (defined as having 293 
an allele count of one in our data set) LoF variants were observed per exome in 294 
SCZ-ID cases compared to controls, while 0.10 (0.065 – 0.13, 95% CI) extra 295 
singleton LoF variants per exome were observed in the remaining schizophrenia 296 
cases compared to controls (Online Methods).  Furthermore, SCZ-ID individuals 297 
had significant enrichment of rare LoF variants in developmental disorder genes 298 
compared to the other cases (P = 9 × 10ିସ; OR 2.36, 1.41– 3.92, 95% CI) or to 299 
controls (P = 9.5 × 10ି଺; OR 3.43, 2.01– 5.86, 95% CI; Figure 4). Compared to 300 
controls, the SCZ-ID individuals carried 0.045 (0.03 – 0.06, 95% CI) extra 301 
singleton LoF variants in developmental disorder genes per exome, suggesting 302 
that around 4% of these cases had a LoF variant that is relevant to their clinical 303 
presentation. No enrichment in neurodevelopmental disorder genes was 304 
observed in schizophrenia patients without intellectual disability, suggesting 305 
that these genes were relevant only for that subset of schizophrenia patients 306 
(Figure 4, Supplementary Table 4). Notably, even after excluding known 307 
developmental disorder genes from the set of LoF intolerant genes, we still 308 
observed an enrichment of rare variants in SCZ-ID patients compared to the 309 
remaining cases (P = 1 × 10ିଷ; 1.26, 1.08 – 1.47, 95% CI) or to controls (P 310 
< 5 × 10ି଻; OR 1.54, 1.31– 1.81, 95% CI; Supplementary Figure 9). Rare variation 311 
in these genes contributes more to disease risk in the subset of patients with 312 
both schizophrenia and intellectual disability.  313 
 314 
Rare variants confer risk for schizophrenia in individuals without intellectual 315 
disability 316 
 317 
 While rare damaging variants in LoF intolerant genes were most enriched 318 
in the subset of schizophrenia patients with intellectual disability, we still 319 
observed a weaker but significant enrichment in individuals with schizophrenia 320 
for whom we could confirm do not have intellectual disability (P = 5.5 × 10ିସ; 321 
1.16, 1.05 – 1.27, 95% CI; Figure 3). Therefore, rare risk variants for 322 
schizophrenia follow the pattern previously described in autism: concentrated in 323 
individuals with intellectual disability, but not exclusive to that group. To 324 
produce a more accurate estimate of the effect of damaging rare variants on 325 
schizophrenia conditional on their effects on overall cognition, we recalculated 326 
the enrichment of rare variants in LoF intolerant genes in a subset of 2,161 327 
schizophrenia cases and 2,398 controls for which data on years of education was 328 
available and for whom intellectual disability could be excluded (Supplementary 329 
Figure 8). After controlling for differences in educational attainment (Online 330 
Methods), individuals with schizophrenia have a 1.26-fold excess of rare variants 331 
in LoF intolerant genes (P = 2 × 10ି଺; 1.14 – 1.38, 95% CI). This increase in our 332 
observed odds ratio is consistent with previous accounts that rare damaging 333 
variants also affect educational attainment in controls39, thus biasing our 334 
unconditional estimate. 335 
Discussion 336 
  337 
  
Our integrated analysis of thousands of whole-exome sequences 338 
demonstrates that rare damaging variants increase risk of schizophrenia both 339 
with and without co-morbid intellectual disability. While the identification of 340 
individual genes remains difficult at current samples sizes, we show that the 341 
burden of damaging de novo mutations, rare SNVs and CNVs in schizophrenia is 342 
not scattered across the genome but is primarily concentrated in 3,488 genes 343 
intolerant of loss-of-function variants. This observation is shared with autism, 344 
intellectual disability, and severe neurodevelopmental disorders32,40. We 345 
recapitulate enrichment in previously published gene sets, including 346 
transmission at glutamatergic synapses and translational regulation by FMRP, 347 
and implicate other gene sets previously linked to autism, intellectual disability, 348 
and severe developmental disorders. However, we find that all of these gene sets 349 
share a large number of underlying genes, and are especially enriched with the 350 
3,488 genes intolerant of LoF variants. These overlaps among gene sets 351 
originating from very different analyses, as well as the subtleties of how they are 352 
defined, suggest caution in interpreting biological explanations from observed 353 
enrichments. 354 
 355 
We jointly analyzed the case-control SNV data with information on 356 
cognitive function for 2,971 patients, and find that LoF variants disrupting genes 357 
associated with severe developmental disorders are disproportionately found in 358 
individuals with schizophrenia with co-morbid intellectual disability, with 4% of 359 
these cases having a single LoF variant that is relevant to their clinical 360 
presentation. Even after excluding variants in known developmental disorder 361 
genes, rare variants contribute a greater degree to schizophrenia risk in the SCZ-362 
ID subgroup of patients than the remaining schizophrenia population. These 363 
results show that some of these genetic perturbations have clear manifestations 364 
in childhood, and that rare risk variants in schizophrenia are particularly 365 
associated with co-morbid intellectual disability. Our observations are consistent 366 
with results in autism in which rare risk variants are associated with intellectual 367 
disability22,23,28.  Notably, a weaker but still significant rare variant burden was 368 
observed in schizophrenia patients without cognitive impairment, and this signal 369 
persists even after controlling for educational attainment. Together, these results 370 
demonstrate that rare variants have different contributions to schizophrenia risk 371 
depending on the degree of cognitive impairment. Importantly, they do not 372 
simply confer risk for a small subset of patients but contribute to disease 373 
pathogenesis more broadly.   374 
 375 
Our study supports the observation that genetic risk factors for 376 
psychiatric and neurodevelopmental disorders do not follow clear diagnostic 377 
boundaries. Coding variants disrupting the same genes, and quite possibly, the 378 
same biological processes, increase risk for a range of phenotypic manifestation. 379 
This clinically variable presentation is reminiscent of LoF variants in SETD1A 380 
and 11 large copy number variant syndromes, previously shown to confer risk 381 
for schizophrenia in addition to other prominent developmental defects16,18. It is 382 
possible that these genes contain an allelic series of variants conferring 383 
gradations of risk. A recent schizophrenia GWAS meta-analysis demonstrated 384 
that the common variant association signal was similarly enriched in LoF 385 
intolerant genes41, suggesting that schizophrenia risk genes may be perturbed by 386 
  
common variants of subtle effects and disrupted by rare variants of high 387 
penetrance in the population. This possibility is also supported by the overlap in 388 
at least some of the pathways affected by both rare and common variation, such 389 
as chromatin remodeling. However, the most common deletion in the 22q11.2 390 
locus and a recurrent two base deletion in SETD1A are associated with both 391 
schizophrenia and more severe neurodevelopmental disorders, suggesting the 392 
same variants can also confer risk for a range of clinical features18,42,43. 393 
Ultimately, it may prove difficult to clearly partition patients genetically into 394 
subtypes with similar clinical features, especially if genes and variants 395 
previously thought to cause well-characterized Mendelian disorders can have 396 
such varied outcomes. This pattern is consistent with the hypothesis that LoF 397 
variants in genes under genic constraint result in a spectrum of 398 
neurodevelopmental outcomes with the burden of mutations highest in 399 
intellectual disability and least in schizophrenia, corresponding to a gradient of 400 
neurodevelopmental pathology indexed by the degree of cognitive impairment, 401 
age of onset, and severity4.  402 
 403 
Despite the complex nature of genetic contributions to risk of 404 
schizophrenia, it is notable that across study design (trio or case-control) and 405 
variant class (SNVs or CNVs), risk loci of large effect are concentrated in a small 406 
subset of genes. Previous rare variant analyses in other neurodevelopmental 407 
disorders, such as autism, have successfully integrated information across de 408 
novo SNVs and CNVs to identify novel risk loci23. As sample sizes increase, meta-409 
analyses leveraging the shared genetic risk across study designs and variant 410 
types, including those we did not consider here, such as classical recessive 411 
inheritance, will be similarly well powered to identify additional risk genes in 412 
schizophrenia. 413 
 414 
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Figure captions 589 
 590 
Figure 1: Analysis workflow. Data sets are shown in blue, statistical methods 591 
and analysis steps are shown in green, and results (figures and tables) from the 592 
analysis are shown in orange. A: Enrichment analyses in 1,766 gene sets using 593 
the entire rare variant data set. B: Enrichment analyses in LoF intolerant and 594 
developmental disorder genes in the subset of cases with information on 595 
cognitive function. ID: intellectual disability; SCZ: schizophrenia; SCZ-ID: 596 
schizophrenia patients with intellectual disability.  597 
Figure 2: Enrichment of schizophrenia rare variants in genes intolerant of loss-598 
of-function variants. A: Schizophrenia cases compared to controls for rare SNVs 599 
and indels; B: Rates of de novo mutations in schizophrenia probands compared 600 
to control probands; C: Case-control CNVs. P-values shown were from the test of 601 
LoF enrichment in A, LoF enrichment in B, and all CNVs enrichment in C. Error 602 
bars represent the 95% CI of the point estimate. LoF intolerant: 3,448 genes with 603 
near-complete depletion of truncating variants in the ExAC database; Rest: the 604 
remaining genes in the genome with pLI < 0.9; Damaging missense: missense 605 
variants with CADD phred > 15. Asterisk: P < 1 x 10-3. 606 
 607 
Figure 3: Enrichment of rare loss-of-function variants in LoF intolerant genes in 608 
schizophrenia cases stratified by information on cognitive function compared to 609 
controls. The P-values shown were calculated using the variant threshold 610 
method comparing LoF burden between the corresponding cases and controls. 611 
Error bars represent the 95% CI of the point estimate. Damaging missense: 612 
missense variants with CADD phred > 15. 613 
 614 
Figure 4: Enrichment of rare loss-of-function variants in known severe 615 
developmental disorder genes in schizophrenia cases stratified by information 616 
on cognitive function compared to controls. The P-values shown were calculated 617 
using the variant threshold method comparing LoF burden between the 618 
corresponding cases and controls. Error bars represent the 95% CI of the point 619 
estimate. Damaging missense: missense variants with CADD phred > 15. 620 
 621 
  
Table 1: Gene sets enriched for rare coding variants conferring risk for schizophrenia at FDR < 1%. The effect sizes and corresponding 622 
P-values from enrichment tests of each variant type (case-control SNVs, DNM, and case-control CNVs) are shown for each gene set, along 623 
with the Fisher’s combined P-value (Pmeta) and the FDR-corrected Q-value (Qmeta). We only show the most significant gene set if there are 624 
multiple ones from the same data set or biological process (see Supplementary Table 1 for all 1,766 gene sets). Ngenes: number of genes 625 
in the gene set; Est: effect size estimate and its lower and upper bound assuming a 95% CI; DNM: de novo mutation.626 
Name Ngenes EstSNV 
95% CI 
of EstSNV 
PSNV EstDNM 
95% CI 
of EstDNM 
PDNM EstCNV 
95% CI 
of EstCNV 
PCNV Pmeta Qmeta 
ExAC LoF intolerant 
genes 
(pLI > 0.9) 
3488 1.24  1.16-1.31 < 5.0 x 10-7 1.36  1.1-1.68 0.0067 1.21  1.15-1.28 0.00026 < 3.60 x 10-10 4.30 x 10-7 
Dominant, diagnostic 
DDG2P genes, in which 
LoF variants result in 
developmental disorders 
with brain abnormalities 
156 1.42  1.07-1.88 0.011 4.18  2.21-8.03 0.00073 1.92  1.54-2.39 0.0016 2.30 x 10-6 0.00067 
Sanders et al. autism risk 
genes (FDR < 10%) 66 1.28  0.97-1.69 0.0095 3.96  1.65-9.94 0.019 2.21  1.75-2.79 0.00033 9.50 x 10
-6 0.0017 
Darnell et al. targets of 
FMRP 790 1.24  1.13-1.36 8.5 x 10
-6 1.31 0.83-2.09 0.17 1.32  1.2-1.47 0.0032 9.30 x 10-7 0.00038 
Cotney et al. CHD8-
targeted promoters (hNSC 
and human brain tissue) 
2920 1.09  1.02-1.16 0.0008 1.77 1.36-2.31 0.00025 1.11  1.05-1.18 0.027 1.10 x 10-6 0.00038 
G2CDB: mouse cortex 
post-synaptic density 
consensus 
1527 1.20  1.11-1.3 2.5 x 10-6 1.57  1.06-2.33 0.028 1.04  0.96-1.11 0.32 3.90 x 10-6 0.00097 
Weynvanhentenryck et al. 
CLIP targets of RBFOX 967 1.21  1.11-1.33 4.8 x 10
-5 1.84  1.21-2.8 0.0085 1.07  0.98-1.17 0.2 1.30 x 10-5 0.002 
NMDAR network (defined 
in Purcell et al.) 61 1.66 1.09-2.54 0.0061 5.60  2.06-16.09 0.017 2.46 1.78-3.4 0.0028 3.70 x 10
-5 0.0044 
GOBP: chromatin 
modification 
(GO:0016568) 
519 1.29  1.13-1.49 0.00018 2.26  1.32-3.94 0.0099 1.12  0.99-1.28 0.18 4.20 x 10-5 0.0046 
  
Supplementary Table captions 627 
 628 
Supplementary Table 1: Full results from enrichment analyses of 1,766 gene 629 
sets. The P-values from enrichment tests of each variant type (case-control SNVs, 630 
DNM, and case-control CNVs) are shown for each gene set, along with the 631 
Fisher’s combined P-value (Pmeta) and the FDR-corrected Q-value (Qmeta). Ngenes: 632 
number of genes in the gene set; SNV: single nucleotide variants from whole-633 
exome data; DNM: de novo mutations. 634 
 635 
Supplementary Table 2: Gene sets enriched for rare coding variants conferring 636 
risk for schizophrenia at FDR < 5%. The effect sizes and corresponding P-values 637 
from enrichment tests of each variant type (case-control SNVs, DNM, and case-638 
control CNVs) are shown for each gene set, along with the Fisher’s combined P-639 
value (Pmeta) and the FDR-corrected Q-value (Qmeta). Ngenes: number of genes in 640 
the gene set; Est: effect size estimate and its lower and upper bound assuming a 641 
95% CI; SNV: single nucleotide variants from whole-exome data; DNM: de novo 642 
mutations. 643 
 644 
Supplementary Table 3: Results from enrichment analyses of FDR < 5% gene 645 
sets, conditional on brain-expressed and ExAC LoF intolerant genes.  We restrict 646 
enrichment analyses to genes that reside in two different background gene sets, 647 
one defined on brain-enriched expression in GTeX, and the second on genic 648 
constraint (ExAC LoF intolerant genes), and determined if gene sets with FDR < 649 
5% in the meta-analysis still had significance above the specific background. The 650 
P-values from enrichment tests of each variant type (case-control SNVs, DNM, 651 
and case-control CNVs) are shown for each gene set, along with the Fisher’s 652 
combined P-value (Pmeta). SNV: single nucleotide variants from whole-exome 653 
data; DNM: de novo mutations 654 
 655 
Supplementary Table 4: Results from enrichment analyses of rare loss-of-656 
function variants in LoF intolerant genes and developmental disorder genes 657 
comparing schizophrenia cases stratified by information on cognitive function 658 
and matched controls. Each comparison is defined in the Table, and the P-values 659 
shown were calculated using the variant threshold method comparing LoF 660 
burden between the corresponding case and baseline samples. Ncase: number of 661 
case samples; Ncomparison: number of comparison samples; Estimates: effect size 662 
estimate and its lower and upper bound assuming a 95% CI. 663 
Online Methods 664 
Sample collections  665 
 666 
The ascertainment, data production, and quality control of the 667 
schizophrenia case-control whole-exome sequencing data set had been 668 
described in detail in an earlier publication18. Briefly, the data set was composed 669 
of schizophrenia cases recruited as part of eight collections in the UK10K 670 
sequencing project, and matched population controls from non-psychiatric arms 671 
of the UK10K project, healthy blood donors from the INTERVAL project, and five 672 
  
Finnish population studies. The UK10K data set was combined and analyzed 673 
with published data from a Swedish schizophrenia case-control study35. The data 674 
production, quality control, and analysis of the case-control CNV data set was 675 
described in an earlier publication29. The schizophrenia cases were recruited as 676 
part of the CLOZUK and CardiffCOGS studies, which consisted of both 677 
schizophrenia individuals taking the antipsychotic clozapine and a general 678 
sample of cases from the UK. Matched controls were selected from four publicly 679 
available non-psychiatric data sets.  All samples were genotyped using Illumina 680 
arrays, and processed and called under the same protocol. Sanger-validated de 681 
novo mutations identified through whole exome-sequencing in seven published 682 
studies of schizophrenia parent-proband trios were aggregated and re-annotated 683 
for enrichment analyses13,44–49. A full description of each trio study, including 684 
sequencing and capture technology and sample recruitment was previously 685 
described18.  686 
Sample and variant quality control 687 
 688 
We jointly called each case data set with its nationality-matched controls, 689 
and excluded samples based on contamination, coverage, non-European 690 
ancestry, and excess relatedness18. A number of empirically derived filters were 691 
applied at the variant and genotype level, including filters on GATK VQSR, 692 
genotype quality, read depth, allele balance, missingness, and Hardy-Weinberg 693 
disequilibrium18. After variant filtering, the per-sample transition-to-694 
transversion ratio was ~3.2 across the entire data set, as expected for 695 
populations of European ancestry50. For the case-control CNV analysis, we 696 
similarly excluded samples based on excess relatedness, and only CNVs 697 
supported by more than 10 probes and greater than 10 kilobases in size were 698 
retained to ensure high quality calls. All de novo mutations in our study had been 699 
validated using Sanger sequencing.  700 
 701 
We used the Ensembl Variant Effect Predictor (VEP) version 75 to 702 
annotate all variants (SNVs and CNVs) according to Gencode v.19 coding 703 
transcripts. We defined frameshift, stop gained, splice acceptor, and donor 704 
variants as loss-of-function (LoF), and missense or initiator codon variants with 705 
the recommended CADD Phred score cut-off of greater than 15 as damaging 706 
missense51. A gene was annotated as disrupted by a deletion if part of its coding 707 
sequence overlapped the copy number event. We more conservatively defined 708 
genes as duplicated only if the entire canonical transcript of the gene overlapped 709 
with the duplication event.  710 
 711 
Statistical tests of the case-control exome data used case-control 712 
permutations within each population (UK, Finnish, Swedish) to generate 713 
empirical P-values to test hypotheses. No genome-wide inflation was observed in 714 
burden tests of individual genes18. In the curated set of de novo mutations, we 715 
observed the expected exome-wide number of synonymous mutations given 716 
gene mutation rates from previously validated models24, suggesting variant 717 
calling was generally unbiased across Gencode v.19 coding genes. Lastly, the 718 
case-control CNV data set had been previously analyzed for burden of CNVs 719 
affecting individual genes, and enrichment analyses in targeted gene sets7,29.  720 
  
Rare variant gene set enrichment analyses 721 
Case-control enrichment burden tests For the case-control SNV data set, we 722 
performed permutation-based gene set enrichment tests using an extension of 723 
the variant threshold method30. This method assumed that variants with a MAF 724 
below an unknown threshold ܶ were more likely to be damaging than variants 725 
with a MAF above ܶ, and this threshold was allowed to differ for every gene or 726 
pathway tested. To consider different possible values for threshold ܶ, a gene or 727 
gene set test statistic ݐ(ܶ) was calculated for every allowable ܶ, and the 728 
maximum test-statistic, or ݐ୫ୟ୶, was selected. The statistical significance of ݐ୫ୟ୶ 729 
was evaluated by permuting phenotypic labels, and calculating ݐ୫ୟ୶ from the 730 
permuted data such that different values of ܶ could be selected following each 731 
permutation. In Price et al., ݐ(ܶ) was defined as the ݖ-score calculated from 732 
regressing the phenotype on the sum of the allele counts of variants in a gene 733 
with MAF < ܶ. We extended this method to test for enrichment in gene sets by 734 
regressing schizophrenia status on the total number of damaging alleles in the 735 
gene set of interest with MAF < ܶ ( ௜ܺ௡,்) while correcting for the total number of 736 
damaging alleles genome-wide with MAF < ܶ (ܺ௔௟௟,்). ܺ௔௟௟,் controlled for 737 
exome-wide differences between schizophrenia cases and controls, ensuring any 738 
significant gene set result was significant beyond baseline differences. ݐ(ܶ) was 739 
defined as the ݐ-statistic testing if the regression coefficient of ௜ܺ௡,் deviated 740 
from 0. We then calculated ݐ(ܶ) for all observed thresholds below a minor allele 741 
frequency of 0.1%, and selected the maximum value for the ݐ୫ୟ୶ based on the 742 
observed data. To calculate a null distribution for ݐ୫ୟ୶, we performed two 743 
million case-control permutations within each population (UK, Finnish, and 744 
Swedish) to control for batch and ancestry, and calculated ݐ୫ୟ୶ for each 745 
permuted sample while allowing ܶ to vary. The ܲ-value for each gene set was 746 
calculated as the fraction of the two million permuted samples that had a greater 747 
ݐ୫ୟ୶ than what was observed in the unpermuted data. The odds ratio and 95% 748 
confidence interval of each gene set was calculated using a logistic regression 749 
model, regressing schizophrenia status on ௜ܺ௡ while controlling for total number 750 
of variants genome-wide (ܺ௔௟௟) and population (UK, Finnish, and Swedish). 751 
Unlike gene set ܲ-values which were calculated using permutation across 752 
multiple frequency thresholds, the odds ratios an d 95% CI were calculated using 753 
only variants observed once in our data set (allele count of 1) to ensure they 754 
were comparable between tested gene sets. 755 
CNV logistic regression We adapted a logistic regression framework described in 756 
Raychaudhuri et al. and implemented in PLINK to compare the case-control 757 
differences in the rate of CNVs overlapping a specific gene set while correcting 758 
for differences in CNV size and total genes disrupted7,19,31. We first restricted our 759 
analyses to coding deletions and duplications, and tested for enrichment using 760 
the following model:  761 
log ൬ ௉೔,ౙ౗౩౛ଵି௉೔,ౙ౗౩౛൰ = ߚ଴ + ߚଵݏ௜ + ߚଶ݃ୟ୪୪ + ߚଷ݃୧୬ + ߳, 762 
where for individual i, pi is the probability they have schizophrenia i, si is the 763 
total length of CNVs, gall is the total number of genes overlapping CNVs, and gin is 764 
the number of genes within the gene set of interest overlapping CNVs. It has been 765 
shown that ߚଵ and ߚଶ sufficiently controlled for the genome-wide differences in 766 
  
the rate and size of CNVs between cases and control, while ߚଷ captured the true 767 
gene set enrichment above this background rate7,19,31. For each gene set, we 768 
reported the one-sided P-value, odds ratio, and 95% confidence interval of ߚଷ.  769 
Weighted permutation-based sampling of de novo mutations For each variant 770 
class of interest, we first determined the total number of de novo mutations 771 
observed in the 1,077 schizophrenia trios. We then generated 2 million random 772 
samples with the same number of de novo mutations, weighting the probability 773 
of observing a mutation in a gene by its estimated mutation rate. The baseline 774 
gene-specific mutation rates were obtained using the method described in 775 
Samocha et al. and adapted to produce LoF and damaging missense rates for 776 
each Gencode v.19 gene. These mutation rates adjusted for both sequence 777 
context and gene length, and were successfully applied in the primary analyses 778 
of large-scale exome sequencing of autism and severe developmental disorders 779 
with replicable results23,32,40. For each gene set, one-sided enrichment P-values 780 
were calculated as the fraction of two million random samples that had a greater 781 
or equal number of de novo mutations in the gene set of interest than what is 782 
observed in the 1,077 trios. The effect size of the enrichment was calculated as 783 
the ratio between the number of observed mutations in the gene set of interest 784 
and the average number of mutations in the gene set across the two million 785 
random samples. We adapted a method in Fromer et al. to calculate 95% credible 786 
intervals for the enrichment statistic13. We first generated a list of one thousand 787 
evenly spaced values between 0 and ten times the point estimate of the 788 
enrichment. For each value, the mutation rates of genes in the gene set of 789 
interest were multiplied by that amount, and 50,000 random samples of de novo 790 
mutations were generated using these weighted rates. The probability of 791 
observing the number of mutations in the gene set of interest given each effect 792 
size multiplier was calculated as the fraction of samples in which the number of 793 
mutations in the gene set is the same as the observed number in the 1,077 trios. 794 
We normalized the probabilities across the 1,000 values to generate a posterior 795 
distribution of the effect size, and calculated the 95% credible interval using this 796 
empirical distribution.  797 
 798 
Combined joint analysis Gene set P-values calculated using the case-control SNV, 799 
case-control CNV, and de novo data were meta-analyzed using Fisher’s combined 800 
probability method with df = 6 to provide a single test statistic for each gene set. 801 
We corrected for the number of gene sets tested in the discovery analysis (n = 802 
1,776) by controlling the false discovery rate (FDR) using the Benjamini-803 
Hochberg approach, and reported only results with a q-value of less than 5%.  804 
 805 
Description of gene sets 806 
 807 
The full list of tested gene sets is found in Supplementary Table 1, and a 808 
detailed description is provided in the Supplementary Note. Briefly, we tested all 809 
gene sets with more than 100 genes from five public pathway databases. We 810 
additionally tested additional gene sets selected based on biological hypotheses 811 
about schizophrenia risk, and genome-wide screens investigating rare variants 812 
in intellectual disability, autism spectrum disorders, and other 813 
neurodevelopmental disorders. All gene identifiers were mapped to the 814 
  
GENCODE v.19 release, and all non-coding genes were excluded. A total of 1,766 815 
gene sets were included in our analysis. 816 
Selection of allele frequency thresholds and consequence severity  817 
 818 
For the case-control whole-exome data, we applied an extension of the 819 
variant threshold model (described above). With this method, we tested 820 
damaging variants at a number of frequency thresholds without specifying an a 821 
priori MAF cut-off. All thresholds below a MAF of 0.1% observed in our data 822 
were tested, and we assessed statistical significance by permutation testing. For 823 
all the whole-exome data (case-control and trio data), we restricted our analyses 824 
to loss-of-function variants. These variants have a clear and severe predicted 825 
functional consequence in that they putatively cause a single-copy loss of a gene. 826 
Furthermore, this class of variants had been demonstrated to have the strongest 827 
genome-wide enrichment between cases and controls across 828 
neurodevelopmental and psychiatric disorders18,32,40. When selecting MAF cut-829 
offs for case-control CNVs, we found that while the bulk of the test statistics were 830 
not inflated, the tail of gene set P-values were dramatically inflated even when 831 
testing for enrichment in the random gene sets (Supplementary Figure 1). This 832 
inflation in the tail of the Q-Q plot was driven in part by very large (overlapping 833 
more than 10 genes), more common (MAF between 0.1% and 1%) CNVs 834 
observed mainly in cases or controls. Some of these, such as the known 835 
syndromic CNVs, likely harbored true risk genes. However, because these CNVs 836 
were highly recurrent in cases and depleted in controls, and disrupted a large 837 
number of genes, any gene set that included even a single gene within these 838 
CNVs would appear to be significant, even after controlling for total CNV length 839 
and genes overlapped. To ensure our model was well calibrated and its P-values 840 
followed a null distribution for random gene sets, we explored different 841 
frequency and size thresholds, and conservatively restricted our analysis to copy 842 
number events overlapping less than seven genes (excluding the largest 10% of 843 
CNVs) with MAF < 0.1% (Supplementary Figure 1). Our main conclusions 844 
remained unchanged even if we selected a more stringent (excluding the largest 845 
15% of CNVs) or less stringent (excluding the largest 5% of CNVs) size threshold. 846 
 847 
Robustness of enrichment analyses 848 
 849 
We uniformly sampled genes from the genome (as defined by Gencode 850 
v.19) to generate random gene sets with the same size distribution as the 1,776 851 
gene sets in our discovery analysis. For each random set, we calculated gene set 852 
P-values for the case-control SNV data, case-control CNV data, and de novo data 853 
using the appropriate method and frequency cut-offs across all variant classes. A 854 
Q-Q plot was generated using P-values from enrichment tests of each data set 855 
and variant type. Reassuringly, we observed null distributions in all such Q-Q 856 
plots (Supplementary Figure 3).  857 
 858 
Comparison of de novo enrichment with broader neurodevelopmental 859 
disorders 860 
 861 
  
We aggregated and re-annotated de novo mutations from four studies: 862 
1,113 severe DD probands40, 4,038 ASD probands23,32, and 2,134 control 863 
probands28,32. We used the Poisson exact test to calculate differences in de novo 864 
rates in constrained genes between schizophrenia, ASD, and DD and controls. 865 
Counts in each functional class (synonymous, missense, damaging missense, and 866 
LoF) were tested separately, and the one-sided P-value, rate ratio, and 95% CI of 867 
each comparison were reported and plotted in Figure 2, Supplementary Figure 4 868 
and 5.  869 
 870 
Conditional analyses 871 
 872 
In each of the three methods we used for gene set enrichment, we 873 
restricted all variants analyzed to those that reside in the background gene list, 874 
and tested for an excess of rare variants in genes shared between the gene set of 875 
interest (K) and the background list (B). Brain-enriched genes from GTEx, and 876 
the ExAC LoF intolerant genes (pLI > 0.9) were used as backgrounds (see above). 877 
For the case-control SNV data, we modified the variant threshold method to 878 
regress schizophrenia status on the total number of damaging alleles in genes 879 
present in both the gene set of interest and the background gene set (ܭ ∩ ܤ), 880 
while correcting for the total number of damaging alleles in the set of all 881 
background genes (ܤ). The logistic regression model for the case-control CNV 882 
data was modified to:  883 
log ൬ ௉೔,ౙ౗౩౛ଵି௉೔,ౙ౗౩౛൰ = ߚ଴ + ߚଵݏ௜ + ߚଶ݃஻ + ߚଷ݃௄ ∩ ஻ + ߳, 884 
where gB is the total number of background genes overlapping a CNV, and ݃௄ ∩ ஻ is 885 
the number of genes in the intersection of the gene set of interest and the 886 
background list overlapping a CNV. Finally, we determined the total number of 887 
de novo mutations within the background gene list observed in the 1,077 888 
schizophrenia trios, and generated 2 million random samples with the same 889 
number of de novo mutations. For each gene set, one-sided enrichment P-values 890 
were calculated as the fraction of two million random samples that had a greater 891 
or equal number of de novo mutations in genes in ܭ ∩  ܤ than what is observed in 892 
the 1,077 trios. Gene set P-values were combined using Fisher’s method. We 893 
restricted our conditional enrichment analysis to gene sets with q-value < 5% in 894 
the discovery analysis, and adjusted for multiple testing using Bonferroni 895 
correction (P = 0.00071, or 0.05/67 tests; see Supplementary Table 3). 896 
 897 
Rare variants and cognition in schizophrenia 898 
 Within the UK10K study, 97 individuals from the MUIR collection were 899 
given discharge diagnoses of mild learning disability and schizophrenia (ICD-8 900 
and -9). The recruitment guidelines of the MUIR collection were described in 901 
detail in a previous publication52. In brief, evidence of remedial education was a 902 
prerequisite to inclusion, and individuals with pre-morbid IQs below 50 or above 903 
70, severe learning disabilities, or were unable to give consent were excluded. 904 
The Schizophrenia and Affective Disorders Schedule-Lifetime version (SADS-L) 905 
in people with mild learning disability, PANSS, RDC, and DSM-III-R, and St. Louis 906 
Criterion were applied to all individuals to ensure that any diagnosis of 907 
  
schizophrenia was robust. Using the clinical information provided alongside the 908 
Swedish and Finnish case-control data sets, we identified additional 182 909 
schizophrenia individuals who were similarly diagnosed with intellectual 910 
disability, for a total of 279 individuals. 911 
Cognitive testing and educational attainment data available for a subset of 912 
samples were used identify schizophrenia individuals without cognitive 913 
impairment. For 502 individuals from the Cardiff collection in the UK10K study, 914 
we acquired their pre-morbid IQ as extrapolated from National Adult Reading 915 
Test (NART), and identified 412 individuals for analysis after excluding all 916 
individuals with predicted pre-morbid IQ of less than 85 (or below one standard 917 
deviation of the population distribution for IQ). We additionally acquired 918 
information on educational attainment in 54 schizophrenia individuals in the 919 
UK10K London collection, and retained 27 individuals without intellectual 920 
disability and who completed at least 12 years of schooling. Lastly, the California 921 
Verbal Learning Test was conducted on 124 Finnish schizophrenia individuals 922 
sequenced as part of UK10K, and a composite score was generated from 923 
measures of verbal and visual working memory, verbal abilities, 924 
visuoconstructive abilities, and processing speed. All individuals with intellectual 925 
disability had been excluded from cognitive testing. Within this set of samples, 926 
we additionally excluded any individuals who ranked in the lowest decile in 927 
CVLT composite score, and retained 92 individuals for analysis. According to 928 
these criteria, we identified 531 of 697 schizophrenia individuals from the UK 929 
and Finnish data sets with cognitive data as not having intellectual disability. We 930 
additionally acquired data on educational attainment for the Swedish 931 
schizophrenia cases and controls from the Swedish National Registry. After 932 
excluding individuals with intellectual disability, we identified 1,527 933 
schizophrenia individuals who did not complete secondary school (less than 12 934 
years of schooling), and 634 schizophrenia individuals who completed at least 935 
compulsory and upper secondary schooling (at least 12 years of schooling). The 936 
last group with the greatest educational attainment and without intellectual 937 
disability was defined as cases without cognitive impairment. In the Swedish 938 
sample, 49.4% of control samples had lower educational attainment than the 939 
634 individuals with schizophrenia defined as having no cognitive impairment, 940 
suggesting that our definition was sufficiently strict. In total, combining the UK, 941 
Finnish, and Swedish data, we identified 1,165 schizophrenia individuals without 942 
cognitive impairment. 943 
Using the variant threshold method, we tested for differences in rare LoF 944 
burden between the three case groups (intellectual disability, did not complete 945 
secondary school, no cognitive impairment) against controls. We restricted these 946 
analyses to three gene sets (LoF intolerant genes, genes in which LoF variants 947 
are diagnostic for severe developmental disorders, and LoF intolerant genes 948 
after excluding severe developmental disorders genes), and adjusted for multiple 949 
testing using Bonferroni correction (P = 0.0038, or 0.05/13 tests). 950 
Supplementary Table 4 enumerated all the statistical tests performed. To 951 
estimate the per-exome excess of rare singleton (defined as having an allele 952 
count of one in our data set) LoF variants in cases compared to controls, we 953 
regressed ௜ܺ௡ (the number of LoF variants in the gene set of interest) on case 954 
status (0 or 1) while controlling for ܺ௔௟௟ (the total number of LoF variants 955 
  
genome-wide) and population (UK, Finnish, and Swedish). The effect size and 956 
95% CI of the regression coefficient of case status predictor were reported.  957 
Data Availability 958 
 959 
Sequence data and processed VCFs for the UK10K project were deposited into 960 
the European Genome-phenome Archive (EGA) under study accession code 961 
EGAO00000000079. The processed VCFs from the Swedish case-control study 962 
were deposited in dbGAP under accession code (phs000473.v1.p1). Rare variant 963 
counts, and gene-level association results from combining the whole-exome 964 
sequencing data sets were described in a previous publication18 and were made 965 
available on the PGC results and download page 966 
(https://www.med.unc.edu/pgc/results-and-downloads). 967 
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